Given the fact that Sirt6 inhibition failed to show an impact on disease course in the therapeutic protocol (where 1 administration was started at disease onset; see Fig. 1 and the “Results” section), SIRT6 is unlikely to represent a viable target for treating the overt MS. Here, SIRT6 is linked to myeloid sarcoma.